Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2004 Sep;75(9):1294–1299. doi: 10.1136/jnnp.2004.037259

Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies

A Bertolotto 1, A Sala 1, S Malucchi 1, F Marnetto 1, M Caldano 1, S Di 1, M Capobianco 1, F Gilli 1
PMCID: PMC1739245  PMID: 15314118

Abstract

Background: MxA gene expression is one of the most appropriate markers of biological activity of exogenous interferon (IFN) beta.

Methods: We quantified MxA mRNA for five consecutive days in 62 patients treated with IFN beta (16, Avonex; 10, Betaferon; 24, Rebif 22; 12, Rebif 44), by quantitative-competitive polymerase chain reaction. Every three months, IFN beta induced neutralising antibodies (NAbs) were evaluated in sera using a cytopathic effect assay.

Results: Two categories of patients were identified: one group (49/62) had a sharp post-injection increase in MxA expression (defined as "IFN beta biological responder"), whereas the other group (13/62) had no MxA induction after IFN beta administrations (defined as "IFN beta biological non-responder"). In 11/13 biological non-responders, the persistent presence of NAbs correlated with abolished biological activity, independently of treatment regimen. The two remaining IFN beta biological non-responders were NAb–. Among the 49 IFN beta biological responders, biological activity was comparable between the four preparations on day 2 and 3 (+12 and +36 hours post-injection), but it was greater in Betaferon and both Rebif preparations on day 1, 4, and 5. In biological responders treated three times a week, only 82% (59/72) of injections were considered effective, compared with 100% (13/13) of Avonex injections.

Conclusion: Our results suggest that an optimal IFN beta regimen is not yet available: Avonex, given once a week, shows lower cumulative biological activity. On the other hand, both Betaferon and Rebif, given three times a week, show 18% biologically ineffective injections and higher risk of developing NAbs, which abolish biological activity.

Full Text

The Full Text of this article is available as a PDF (144.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antonelli G., Bagnato F., Pozzilli C., Simeoni E., Bastianelli S., Currenti M., De Pisa F., Fieschi C., Gasperini C., Salvetti M. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a. J Interferon Cytokine Res. 1998 May;18(5):345–350. doi: 10.1089/jir.1998.18.345. [DOI] [PubMed] [Google Scholar]
  2. Arnason B. G., Dayal A., Qu Z. X., Jensen M. A., Genç K., Reder A. T. Mechanisms of action of interferon-beta in multiple sclerosis. Springer Semin Immunopathol. 1996;18(1):125–148. doi: 10.1007/BF00792613. [DOI] [PubMed] [Google Scholar]
  3. Bertolotto A., Gilli F., Sala A., Audano L., Castello A., Magliola U., Melis F., Giordana M. T. Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods. 2001 Oct 1;256(1-2):141–152. doi: 10.1016/s0022-1759(01)00434-3. [DOI] [PubMed] [Google Scholar]
  4. Bertolotto A., Gilli F., Sala A., Capobianco M., Malucchi S., Milano E., Melis F., Marnetto F., Lindberg R. L. P., Bottero R. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology. 2003 Feb 25;60(4):634–639. doi: 10.1212/01.wnl.0000046662.03894.c5. [DOI] [PubMed] [Google Scholar]
  5. Bertolotto A., Malucchi S., Milano E., Castello A., Capobianco M., Mutani R. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology. 2000 Jul 20;48(2):95–100. doi: 10.1016/s0162-3109(00)00182-x. [DOI] [PubMed] [Google Scholar]
  6. Bertolotto A., Malucchi S., Sala A., Orefice G., Carrieri P. B., Capobianco M., Milano E., Melis F., Giordana M. T. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry. 2002 Aug;73(2):148–153. doi: 10.1136/jnnp.73.2.148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chiang J., Gloff C. A., Yoshizawa C. N., Williams G. J. Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin. Pharm Res. 1993 Apr;10(4):567–572. doi: 10.1023/a:1018902120023. [DOI] [PubMed] [Google Scholar]
  8. Comi G., Filippi M., Barkhof F., Durelli L., Edan G., Fernández O., Hartung H., Seeldrayers P., Sørensen P. S., Rovaris M. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001 May 19;357(9268):1576–1582. doi: 10.1016/s0140-6736(00)04725-5. [DOI] [PubMed] [Google Scholar]
  9. Deisenhammer F., Reindl M., Harvey J., Gasse T., Dilitz E., Berger T. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology. 1999 Apr 12;52(6):1239–1243. doi: 10.1212/wnl.52.6.1239. [DOI] [PubMed] [Google Scholar]
  10. Dupont Stefan A., Goelz Susan, Goyal Jaya, Green Marie. Mechanisms for regulation of cellular responsiveness to human IFN-beta1a. J Interferon Cytokine Res. 2002 Apr;22(4):491–501. doi: 10.1089/10799900252952280. [DOI] [PubMed] [Google Scholar]
  11. Gilli Francesca, Bertolotto Antonio, Sala Arianna, Hoffmann Francine, Capobianco Marco, Malucchi Simona, Glass Tracy, Kappos Ludwig, Lindberg Raija L. P., Leppert David. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. Brain. 2003 Nov 7;127(Pt 2):259–268. doi: 10.1093/brain/awh028. [DOI] [PubMed] [Google Scholar]
  12. Grossberg S. E., Kawade Y., Kohase M., Klein J. P. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res. 2001 Sep;21(9):743–755. doi: 10.1089/107999001753124471. [DOI] [PubMed] [Google Scholar]
  13. J. Stephen Fink, MD, PhD (1950-2002). Neurology. 2003 Dec 9;61(11 Suppl 6):S1–111. doi: 10.1212/01.wnl.0000095201.55121.8a. [DOI] [PubMed] [Google Scholar]
  14. Jacobs L. D., Beck R. W., Simon J. H., Kinkel R. P., Brownscheidle C. M., Murray T. J., Simonian N. A., Slasor P. J., Sandrock A. W. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000 Sep 28;343(13):898–904. doi: 10.1056/NEJM200009283431301. [DOI] [PubMed] [Google Scholar]
  15. Jacobs L. D., Cookfair D. L., Rudick R. A., Herndon R. M., Richert J. R., Salazar A. M., Fischer J. S., Goodkin D. E., Granger C. V., Simon J. H. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol. 1996 Mar;39(3):285–294. doi: 10.1002/ana.410390304. [DOI] [PubMed] [Google Scholar]
  16. Kastrukoff L. F., Morgan N. G., Zecchini D., White R., Petkau A. J., Satoh J., Paty D. W. Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B. Neurology. 1999 Jan 15;52(2):351–359. doi: 10.1212/wnl.52.2.351. [DOI] [PubMed] [Google Scholar]
  17. Kawade Y. Quantitation of neutralization of interferon by antibody. Methods Enzymol. 1986;119:558–573. doi: 10.1016/0076-6879(86)19076-8. [DOI] [PubMed] [Google Scholar]
  18. Kracke A., von Wussow P., Al-Masri A. N., Dalley G., Windhagen A., Heidenreich F. Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS. Neurology. 2000 Jan 11;54(1):193–199. doi: 10.1212/wnl.54.1.193. [DOI] [PubMed] [Google Scholar]
  19. McDonald W. I., Compston A., Edan G., Goodkin D., Hartung H. P., Lublin F. D., McFarland H. F., Paty D. W., Polman C. H., Reingold S. C. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 Jul;50(1):121–127. doi: 10.1002/ana.1032. [DOI] [PubMed] [Google Scholar]
  20. Pachner Andrew R., Bertolotto Antonio, Deisenhammer Florian. Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB). Neurology. 2003 Nov 11;61(9 Suppl 5):S24–S26. doi: 10.1212/01.wnl.0000092361.04511.d0. [DOI] [PubMed] [Google Scholar]
  21. Paul W. E., Seder R. A. Lymphocyte responses and cytokines. Cell. 1994 Jan 28;76(2):241–251. doi: 10.1016/0092-8674(94)90332-8. [DOI] [PubMed] [Google Scholar]
  22. Ross C., Clemmesen K. M., Svenson M., Sørensen P. S., Koch-Henriksen N., Skovgaard G. L., Bendtzen K. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol. 2000 Nov;48(5):706–712. [PubMed] [Google Scholar]
  23. Rothuizen L. E., Buclin T., Spertini F., Trinchard I., Munafo A., Buchwalder P. A., Ythier A., Biollaz J. Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers. J Neuroimmunol. 1999 Sep 1;99(1):131–141. doi: 10.1016/s0165-5728(99)00029-6. [DOI] [PubMed] [Google Scholar]
  24. Rudick R. A., Ransohoff R. M., Lee J. C., Peppler R., Yu M., Mathisen P. M., Tuohy V. K. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology. 1998 May;50(5):1294–1300. doi: 10.1212/wnl.50.5.1294. [DOI] [PubMed] [Google Scholar]
  25. Sorensen Per Soelberg, Ross Christian, Clemmesen Katja Maria, Bendtzen Klaus, Frederiksen Jette Lautrup, Jensen Kai, Kristensen Ole, Petersen Thor, Rasmussen Soren, Ravnborg Mads. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet. 2003 Oct 11;362(9391):1184–1191. doi: 10.1016/S0140-6736(03)14541-2. [DOI] [PubMed] [Google Scholar]
  26. Vallittu A-M, Halminen M., Peltoniemi J., Ilonen J., Julkunen I., Salmi A., Erälinna J-P, Finnish Beta-Interferon Study Group Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients. Neurology. 2002 Jun 25;58(12):1786–1790. doi: 10.1212/wnl.58.12.1786. [DOI] [PubMed] [Google Scholar]
  27. Weinstock-Guttman B., Ransohoff R. M., Kinkel R. P., Rudick R. A. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol. 1995 Jan;37(1):7–15. doi: 10.1002/ana.410370105. [DOI] [PubMed] [Google Scholar]
  28. Williams G. J., Witt P. L. Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX. J Interferon Cytokine Res. 1998 Nov;18(11):967–975. doi: 10.1089/jir.1998.18.967. [DOI] [PubMed] [Google Scholar]
  29. Witt P. L., Storer B. E., Bryan G. T., Brown R. R., Flashner M., Larocca A. T., Colby C. B., Borden E. C. Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta. J Immunother Emphasis Tumor Immunol. 1993 Apr;13(3):191–200. doi: 10.1097/00002371-199304000-00006. [DOI] [PubMed] [Google Scholar]
  30. von Wussow P., Jakschies D., Hochkeppel H. K., Fibich C., Penner L., Deicher H. The human intracellular Mx-homologous protein is specifically induced by type I interferons. Eur J Immunol. 1990 Sep;20(9):2015–2019. doi: 10.1002/eji.1830200920. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES